Response to Song

Affiliations

¹ Clinical Investigations Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, USA.
² Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, USA.

Comment

Larissa A Korde et al. J Natl Cancer Inst. 2023.

. 2023 Jun 8;115(6):768.

doi: 10.1093/jnci/djad054.

¹ Clinical Investigations Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, USA.
² Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, USA.

No abstract available

Conflict of interest statement

None reported.

RE: COVID-19 severity by vaccination status in the NCI COVID-19 and Cancer Patients Study (NCCAPS).
Song S. Song S. J Natl Cancer Inst. 2023 Jun 8;115(6):766-767. doi: 10.1093/jnci/djad045. J Natl Cancer Inst. 2023. PMID: 36946282 Free PMC article. No abstract available.

1. Song S. RE: COVID-19 severity by vaccination status in the NCI COVID-19 and cancer patients study (NCCAPS). J Natl Cancer Inst. 2023;115(6):766–767. - PMC - PubMed
1. Levin MJ, Ustianowski A, De Wit S, et al.; for the PROVENT Study Group. Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of COVID-19. N Engl J Med. 2022;386(23):2188-2200. - PMC - PubMed
1. Montgomery H, Hobbs FDR, Padilla F, et al.; for the TACKLE Study Group. Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2022;10(10):985-996. - PMC - PubMed